 OSLO, Norway CAMBRIDGE, Mass.--BUSINESS WIRE--- VBIV--CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. Nasdaq: VBIV, today announced a partnership to develop VBIs enveloped virus like particle eVLP vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant, also known as 501Y.V2, first identified in South Africa. CEPI will provide up to 33m to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of t 